1-phenyl-2-pyridinyl alkyl alcohol compounds as phosphodiesterase inhibitors

A combination, comprising at least one compound of formula (I) as an (−) enantiomer

• wherein:
• n is 0 or 1;
• R1 and R2 may be the same or different, and are selected from the group consisting of:
• linear or branched C1-C6 alkyl, optionally substituted by one or more halogen atoms;
• —OR3 wherein R3 is a linear or branched C1-C6 alkyl optionally substituted with one or more halogen atoms or C3-C7 cycloalkyl groups;
• and
• —NHSO2R4 wherein R4 is a linear or branched C1-C4 alkyl optionally substituted with one or more halogen atoms,
• wherein at least one of R1 and R2 is —NHSO2R4,
• or a pharmaceutically acceptable salt thereof;
• and
• at least one second pharmaceutical active component selected from the group consisting of a long-acting β2 agonist, a M3 antagonist, and a corticosteroid,
• wherein:
• said β2 agonist is selected from the group consisting of carmoterol, GSK-642444, indacaterol, milveterol, arformoterol, formoterol, salbutamol, formoterol, levalbuterol, terbutaline, AZD-3199, BI-1744-CL, LAS-100977, bambuterol, isoproterenol, procaterol, clenbuterol, reproterol, fenoterol and ASF-1020;
• said M3 antagonist is selected from the group consisting of aclidinium, tiotropium, ipratropium, and oxitropium;
• and
• said corticosteroid is selected from the group consisting of dexamethasone, fluticasone, fluticasone furoate, prednisolone, betamethasone, budesonide, mometasone, mometasone furoate, triamcinolone acetonide, ciclesonide, TPI-1020, beclomethasone, beclomethasone dipropionate, prednisone, deflazacort, hydrocortisone, QAE-397, and flunisolide.